Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease

Journal of Gastroenterology

Volumn 47, Issue 12, 2012, Pages 1298-1307

  Andoh, Akira ^a   Kuzuoka, Hiroyuki ^b,c   Tsujikawa, Tomoyuki ^a   Nakamura, Shiro ^b   Hirai, Fumihito ^d   Suzuki, Yasuo ^e   Matsui, Toshiyuki ^d   Fujiyama, Yoshihide ^a   Matsumoto, Takayuki ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d Fukuoka University Chikushi Hospital   (Japan)

^e TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Faecalibacterium; Firmicutes; Inflammatory bowel disease; Shannon diversity index; T RFLP

Indexed keywords

CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE;

ADULT; ARTICLE; BACTERIAL COUNT; BACTERIAL DIVERSITY; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIA; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERIC FEEDING; FAECALIBACTERIUM; FEASIBILITY STUDY; FECES ANALYSIS; FECES MICROFLORA; FEMALE; GENE CLUSTER; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOLOGICAL PARAMETERS; NONHUMAN; NUCLEIC ACID ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; SHANNON DIVERSITY INDEX; TERMINAL RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; BACTERIA; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIUM; CROHN DISEASE; FEASIBILITY STUDIES; FECES; FEMALE; HUMANS; MALE; METAGENOME; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REMISSION INDUCTION;

EID: 84875717908     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0605-0     Document Type: Article

References (48)

1. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007;42:16-25.
2. Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9-16.
3. Hibi T, Ogata H. Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol. 2006;41:10-6.
4. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29. (Pubitemid 34851835)
5. Hamilton MJ, Snapper SB, Blumberg RS. Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance. J Gastroenterol. 2012;47:1-8.
6. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-94. (Pubitemid 351173057)
7. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008;43:1-17. (Pubitemid 351324980)
8. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407. (Pubitemid 44018812)
9. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev. 2007;59:1073-83. (Pubitemid 47615208)
10. Braun J, Wei B. Body traffic: ecology, genetics, and immunity in inflammatory bowel disease. Annu Rev Pathol. 2007;2:401-29. (Pubitemid 46448071)
11. Seksik P, Sokol H, Lepage P, Vasquez N, Manichanh C, Mangin I, et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(Suppl 3):11-8. (Pubitemid 44326413)
12. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206:260-76. (Pubitemid 41105175)
13. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-6. (Pubitemid 32531409)
14. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008;456:259-63.
15. Kabi A, Nickerson KP, Homer CR, McDonald C. Digesting the genetics of inflammatory bowel disease: Insights from studies of autophagy risk genes. Inflamm Bowel Dis. 2012;18:782-92.
16. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780-5. (Pubitemid 350003397)
17. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol. 2000;15:61-8. (Pubitemid 30140928)
18. Lucke K, Miehlke S, Jacobs E, Schuppler M. Prevalence of Bacteroides and Prevotella spp. in ulcerative colitis. J Med Microbiol. 2006;55:617-24.
19. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54. (Pubitemid 34049193)
20. Hayashi H, Sakamoto M, Benno Y. Phylogenetic analysis of the human gut microbiota using 16S rDNA clone libraries and strictly anaerobic culture-based methods. Microbiol Immunol. 2002;46:535-48. (Pubitemid 34947852)
21. Langendijk PS, Schut F, Jansen GJ, Raangs GC, Kamphuis GR, Wilkinson MH, et al. Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol. 1995;61:3069-75.
22. Andoh A, Benno Y, Kanauchi O, Fujiyama Y. Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr Pharm Des. 2009;15:2066-73.
23. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis. 2012;18:968-84.
24. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46:479-86.
25. Andoh A, Tsujikawa T, Sasaki M, Mitsuyama K, Suzuki Y, Matsui T, et al. Fecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism (t-rflp) analysis. Aliment Pharmacol Ther. 2009;29:75-82.
26. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691-6.
27. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-44.
28. Matsumoto M, Sakamoto M, Hayashi H, Benno Y. Novel phylogenetic assignment database for terminal-restriction fragment length polymorphism analysis of human colonic microbiota. J Microbiol Methods. 2005;61:305-19. (Pubitemid 40568582)
29. Sakamoto M, Takeuchi Y, Umeda M, Ishikawa I, Benno Y. Application of terminal RFLP analysis to characterize oral bacterial flora in saliva of healthy subjects and patients with periodontitis. J Med Microbiol. 2003;52:79-89. (Pubitemid 36106373)
30. Marsh TL, Saxman P, Cole J, Tiedje J. Terminal restriction fragment length polymorphism analysis program, a web-based research tool for microbial community analysis. Appl Environ Microbiol. 2000;66:3616-20. (Pubitemid 30624605)
31. Hill TC, Walsh KA, Harris JA, Moffett BF. Using ecological diversity measures with bacterial communities. FEMS Microbiol Ecol. 2003;43:1-11. (Pubitemid 36173508)
32. Chiang JK, Cheng YH, Koo M, Kao YH, Chen CY. A computer-assisted model for predicting probability of dying within 7 days of hospice admission in patients with terminal cancer. Jpn J Clin Oncol. 2010;40:449-55.
33. Andoh A, Sakata S, Koizumi Y, Mitsuyama K, Fujiyama Y, Benno Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:955-62. (Pubitemid 47309966)
34. Nishikawa J, Kudo T, Sakata S, Benno Y, Sugiyama T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol. 2009;44:180-6.
35. Nomura T, Ohkusa T, Okayasu I, Yoshida T, Sakamoto M, Hayashi H, et al. Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy. Aliment Pharmacol Ther. 2005;21:1017-27. (Pubitemid 40529736)
36. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.
37. Schutte UM, Abdo Z, Bent SJ, Shyu C, Williams CJ, Pierson JD, et al. Advances in the use of terminal restriction fragment length polymorphism (T-RFLP) analysis of 16S rRNA genes to characterize microbial communities. Appl Microbiol Biotechnol. 2008;80:365-80.
38. Kurokawa K, Itoh T, Kuwahara T, Oshima K, Toh H, Toyoda A, et al. Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes. DNA Res. 2007;14:169-81.
39. Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:607-13. (Pubitemid 47268226)
40. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol. 2007;23:16-20. (Pubitemid 44875904)
41. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337-41.
42. Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, et al. Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity. 2008;29:637-49.
43. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105:16731-6.
44. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183-9.
45. Duncan SH, Hold GL, Harmsen HJ, Stewart CS, Flint HJ. Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int J Syst Evol Microbiol. 2002;52:2141-6. (Pubitemid 36004196)
46. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444:1022-3. (Pubitemid 46018512)
47. Aomatsu T, Imaeda H, Matsumoto K, Kimura E, Yoden A, Tamai H, et al. Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:941-8.
48. Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, et al. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372-7.